Day: December 13, 2022

TORONTO, ON, Dec. 13, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that the United States Patent and Trademark Office (USPTO) recently issued patent No. 11,504,191, titled “Graphical User Interface for a Robotic Surgical System.” The patent, directed at enhancing the surgeon user experience, generally covers a graphical user interface (GUI) overlay of a surgical workspace to track instrument movement. “The granting of this patent is a result of our strategic plan to independently build and protect a robust patent portfolio in robotic assisted surgery, including around the Enos™ robotic single access surgical system. Today’s...

Exploration Permit Received for Oakes Project Area TORONTO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Sparton Resources Inc. (the “Company”) (“SRI”-TSX-V) is pleased to report summary results from the Eldorado Gold Corporation drill program, completed at the Company’s Bruell property east of Val d’Or Quebec. On October 26, 2022, Sparton reported that it has completed the earn-in and exercised its option to acquire 100% of the 51 claim Bruell Property in Vauquelin Township, Quebec (the “Bruell Property”) from the underlying vendors. Please see Company news release dated October 26, 2022, for details. It was also announced at that time that Eldorado had requested, and Sparton had agreed to a one-year extension on the Eldorado Option Agreement. In consideration for the extension, Eldorado has agreed to carry out a minimum of 4,000 meters of...

Figure 1 Location of the Langis Project, OntarioFigure 2 Collar Locations and Drill Traces at the Langis ProjectFigure 3 High-grade cobalt intercept from hole LM-22-254Figure 4 Examples of Cobalt Mineralized Veins from hole LM-22-254VANCOUVER, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce the first batch of drill results from its wholly owned Langis Project. The project is located in the Cobalt Camp of Ontario which is about 500km north from Toronto. The objective of the 2022 drill program was to test the cobalt-nickel domain at the Langis Project. The program started in early November with 7,000m planned and should be completed around the 20th of December. The project is situated within the Timiskaming First...

Nubeva’s Ransomware Reversal Solution successfully decrypts Black Basta attack on customer SAN JOSE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — Nubeva Technologies (TSX-V: NBVA, OTCQB: NBVAF) today announced the successful decryption of Black Basta ransomware for a customer. This is one of the latest in a growing list of successful decryptions by Nubeva, including lethal threat actors such as Conti, Hive, LockBit, Ragnar Locker, Blackcat, and REvil across multiple industries. Details of the customer and ransomware attack are subject to confidentiality agreements. “In this attack, a significant amount of data was also corrupted on top of catastrophic data encryption. Typically, threat actors cannot recover corrupted data even after a ransom payment. But Nubeva’s technology often can,” said Steve Perkins, Nubeva CMO. “In this case,...

Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sites Primary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall weighted average specificity of 97.4% in preliminary analysis Clinical performance results will be used to prepare submission package for FDA De Novo requestROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced top line data from its successfully completed Unyvero UTI clinical trial. OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens....

FREMONT, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, announced it received ISO 9001:2015 certification, a rigorous international evaluation process that validates the company’s end-to-end business processes meet industry-recognized standards. ISO 9001:2015 is a certification from the International Organization for Standardization, an independent, non-governmental body that ensures companies provide their customers with consistent, quality products and services. “Achieving 3rd party certification of ISO 9001:2015 validates our dedication and hard work over the last two years developing a robust Quality Management System (QMS) and enterprise business process that our customers expect,” said...

Xtract One Technologies Announces Tachi Palace Casino Resorts To Expand Use Of Safegateway Weapons Detection Technology Xtract One Technologies Announces Tachi Palace Casino Resorts To Expand Use Of Safegateway Weapons Detection TechnologyTORONTO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) today announced that Tachi Palace Casino Resorts (“Tachi”), located in Lemoore, Calif., has expanded its use of Xtract One’s SafeGateway weapons detection technology to accommodate the venue’s growth. Tachi, owned by the Tachi-Yokut Native American tribe, first purchased Xtract One gateway technology in July 2021. The new resort expansion spans more than 300,000 square feet, encompassing a casino, hotel and resort, entertainment center, gas station and more....

Figure 1: East Preston Project Location – Western Athabasca Basin, Saskatchewan, Canada Figure 1: East Preston Project Location – Western Athabasca Basin, Saskatchewan, CanadaFigure 2: 2022 Drill Holes and Target areas at the East Preston Uranium Project Figure 2: 2022 Drill Holes and Target areas at the East Preston Uranium ProjectVANCOUVER British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) — AZINCOURT ENERGY CORP. (“Azincourt” or the “Company”) (TSX.V: AAZ, OTCQB: AZURF), is pleased to announce that approvals have been received for the upcoming winter drill program at the East Preston uranium project, in the Athabasca Basin, Saskatchewan, Canada. Preparations continue for the winter program at the East Preston project. Permits and approval for the program have been received and the company will continue to work with the Clearwater...

Cellectis’ Pipeline Overview Cellectis’ Fully Owned & Licensed Product Candidate PipelineUCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that continues beyond 12 months BALLI-01 study (evaluating UCART22) now enrolling patients with product candidate manufactured in-house at DL2 AMELI-01 study (evaluating UCART123) now enrolling patients in a two-dose regimen arm at DL2NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...

Cellectis’ Pipeline Overview Cellectis’ Fully Owned & Licensed Product Candidate PipelineUCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that continues beyond 12 months BALLI-01 study (evaluating UCART22) now enrolling patients with product candidate manufactured in-house at DL2 AMELI-01 study (evaluating UCART123) now enrolling patients in a two-dose regimen arm at DL2NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...